Report cover image

Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review

Publisher GlobalData
Published May 04, 2026
Length 95 Pages
SKU # GBDT21162351

Description

Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Eli Lilly and Co (Lilly) is a pharmaceutical company that discovers, develops, manufactures, and markets human healthcare products. Its major products focus on therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience. The company distributes its pharmaceutical health products through independent wholesale distributors through the brands Basaglar, Humalog, Jardiance, Trulicity, Cyramza, and Emgality to wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. The company operates R&D facilities, and production and distribution facilities in North America, South America, Europe, the Middle East, Africa, and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

May 01,2026: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
Apr 29,2026: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Apr 20,2026: Indiana Governor Signs Nuclear Energy Letter of Intent with Eli Lilly and Company
Apr 16,2026: Developers back Alzheimer’s drugs despite report suggesting lack of efficacy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Opportunities thaented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company

Table of Contents

95 Pages
Section 1 - About the Company
Eli Lilly and Co - Key Facts
Eli Lilly and Co - Key Employees
Eli Lilly and Co - Key Employee Biographies
Eli Lilly and Co - Major Products and Services
Eli Lilly and Co - History
Eli Lilly and Co - Company Statement
Eli Lilly and Co - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Eli Lilly and Co - Business Description
Product Category: Cardiometabolic Health
Overview
Performance
Product Category: Immunology
Overview
Performance
Product Category: Neuroscience
Overview
Performance
Product Category: Oncology
Overview
Performance
Product Category: Other
Overview
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: U.S.
Performance
R&D Overview
Eli Lilly and Co - Corporate Strategy
Eli Lilly and Co - SWOT Analysis
SWOT Analysis - Overview
Eli Lilly and Co - Strengths
Eli Lilly and Co - Weaknesses
Eli Lilly and Co - Opportunities
Eli Lilly and Co - Threats
Eli Lilly and Co - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Eli Lilly and Co, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 01, 2026: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
Apr 29, 2026: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Apr 20, 2026: Indiana Governor Signs Nuclear Energy Letter of Intent with Eli Lilly and Company
Apr 16, 2026: Developers back Alzheimer’s drugs despite report suggesting lack of efficacy
Apr 16, 2026: Lilly Confirms Date and Conference Call for First-Quarter 2026 Financial Results
Apr 15, 2026: Lilly to acquire CrossBridge Bio for up to $300m
Apr 15, 2026: Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics
Apr 14, 2026: Vasa Therapeutics Partners With Lilly TuneLab to Advance AI/ML-Driven CAMKII Inhibitor Discovery
Apr 13, 2026: Lilly's Jaypirca Extends Progression-Free Survival When Added to Venetoclax Time-Limited Regimen in Previously Treated CLL/SLL
Apr 09, 2026: Foundayo (orforglipron), Lilly's Oral GLP-1 Pill for Weight Loss Now Available in the United States
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Eli Lilly and Co, Key Facts
Eli Lilly and Co, Key Employees
Eli Lilly and Co, Key Employee Biographies
Eli Lilly and Co, Major Products and Services
Eli Lilly and Co, History
Eli Lilly and Co, Subsidiaries
Eli Lilly and Co, Joint Venture
Eli Lilly and Co, Key Competitors
Eli Lilly and Co, Ratios based on current share price
Eli Lilly and Co, Annual Ratios
Eli Lilly and Co, Annual Ratios (Cont...1)
Eli Lilly and Co, Annual Ratios (Cont...2)
Eli Lilly and Co, Interim Ratios
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Eli Lilly and Co, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Eli Lilly and Co, Performance Chart (2021 - 2025)
Eli Lilly and Co, Ratio Charts
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.